艾拉莫德治疗干燥综合征合并肺间质病变的疗效评价

Evaluation on efficacy of iguratimod on Sjogren’s syndrome complicated with pulmonary interstitial lesions

目的探讨艾拉莫德在干燥综合征合并肺间质病变中的治疗效果。方法 200例干燥综合征合并肺间质病变患者,随机分为观察组和对照组,每组100例。对照组患者均给予对症治疗,观察组患者在对照组基础上加用艾拉莫德治疗。比较两组患者治疗前后血沉(ESR)、免疫球蛋白G(IgG)、肺功能指标[用力肺活量(FVC)、最大呼气中期流速(MMF)]及不良反应发生情况。结果治疗前,两组患者的ESR、IgG水平比较差异均无统计学意义(P>0.05);治疗后,观察组患者的ESR(24.01±3.24)mm/h、IgG(14.03±2.17)g/L均低于对照组的(27.00±3.51)mm/h、(17.91±2.60)g/L,差异均具有统计学意义(P<0.05)。治疗前,两组患者的FVC、MMF水平比较差异均无统计学意义(P>0.05);治疗后,观察组患者的FVC为(1.98±0.28)L、MMF为(1.57±0.40)L/s,均高于对照组的(1.69±0.33)L、(1.42±0.37)L/s,差异均具有统计学意义(P<0.05)。随访结束时,观察组患者的不良反应发生率5.00%与对照组的3.00%比较,差异无统计学意义(P>0.05)。结论干燥综合征合并肺间质病变采用艾拉莫德治疗安全有效,能改善患者的肺功能,控制炎性反应,且不良反应轻微。

Objective To discuss the therapeutic effect of iguratimod on Sjogren’s syndrome complicated with pulmonary interstitial lesions. Methods A total of 200 patients with Sjogren’s syndrome complicated with pulmonary interstitial lesions were randomly divided into observation group and control group, with 100 cases in each group. The control group received symptomatic therapy, and the observation group received iguratimod for treatment on the basis of the control group. Comparison was made on erythrocyte sedimentation rate(ESR), immunoglobulin G(IgG), pulmonary function indicators [forced vital capacity(FVC), maximum midexpiratory flow(MMF)] before and after treatment and occurrence of adverse reactions between the two groups. Results Before treatment, there was no statistically significant difference in levels of ESR and IgG between the two groups(P>0.05). After treatment, the ESR(24.01±3.24) mm/h and IgG(14.03±2.17) g/L in the observation group was lower than(27.00±3.51) mm/h and(17.91±2.60) g/L in the control group, and their difference was statistically significant(P<0.05). Before treatment, there was no statistically significant difference in levels of FVC and MMF between the two groups(P>0.05). After treatment, the FVC(1.98±0.28) L and MMF(1.57±0.40) L/s in the observation group was(1.69±0.33) L and(1.42±0.37) L/s in the control group, and their difference was statistically significant(P<0.05). At the end of follow-up, there was no statistically significant incidence of adverse reactions as 5.00% in the observation group, compared with 3.00% in the control group(P>0.05). Conclusion Iguratimod is safe and effective in Sjogren’s syndrome complicated with pulmonary interstitial lesions, and it can improve the pulmonary function of patients and control inflammatory reaction with slight adverse reactions.